Founders: Dr. Oran Rigby & Dr. Amy Hollingworth
Consultant: Intensive Care Medicine in Dublin
Professor: Robotics and Autonomous Systems
Masters: Public Health Disaster Medicine, Trauma Surgery and Orthopaedic Medicine
Cosultant: Respiratory + Lung Transplant Specialist
Masters: Public Health Disaster Medicine, focusing on Pandemic Influenza
Medical Director: Sydney / NSW State Trauma System (Retd)
Aero Medical Director: Sydney / NSW State Counter Disaster (Retd)
Churchill Scholarship: 2014 Australian Churchill Scholarship for Telemedicine Research...
The COVID-19 MedBot is powered by Akkure, an innovative digital health startup based in Dublin. Akkure’s vision is to put control over health and medical data back into the hands of patients. We have designed a block-chain enabled digital health platform that allows users to own their own genetic information. Akkure’s platform enables users to keep their information private, or, if they choose to do so, be rewarded fiscally for sharing their information anonymously and securely with research organizations.
By joining the Akkure network, you are not only actively facilitating medical breakthroughs, but furthermore, becoming part of an innovative, patient focused, medical community looking to improve public health and revolutionize modern medicine.
Read more about the release of the COVID Medbot.
- Transcript for the CDC Telebriefing Update on COVID-19Transcript for the CDC Telebriefing: Update on 2019 Novel Coronavirus (2019-nCoV)
- HHS Announces New Organ Transplant GuidanceToday, the U.S. Department of Health and Human Services and the U.S. Public Health Service (USPHS) published an updated <a href="https://www.cdc.gov/mmwr/volumes/69/rr/rr6904a1.htm?s_cid=rr6904a1_w">solid organ transplant guideline</a> to assess donors and monitor recipients for human immunodeficiency virus (HIV), hepatitis B virus, and hepatitis C virus infections.
- CDC Marks the End of the 2018 Ebola Outbreak in Eastern Democratic Republic of the CongoThe U.S. Centers for Disease Control and Prevention (CDC) is joining the global public health community to mark the end of the Ebola Virus Disease (Ebola) outbreak in the eastern part of the Democratic Republic of the Congo (DRC).
- Coronavirus could cause 35,000 extra UK cancer deaths, experts warnThe research is based on the number of missed screenings, urgent referrals and delayed treatments.
- PM joins nationwide clap on NHS 72nd anniversaryThe applause was inspired by the weekly Clap for Carers during the peak of the coronavirus lockdown.
- Coronavirus: NHS England launches tool to aid long-term recoveryAn online portal will launch in England later this month to help people with ongoing symptoms.
- WHO discontinues hydroxychloroquine and lopinavir/ritonavir treatment arms for COVID-19<p dir="ltr"></p> <p dir="ltr">WHO today accepted the recommendation from the Solidarity Trial’s International Steering Committee to discontinue the trial’s hydroxychloroquine and lopinavir/ritonavir arms. The Solidarity Trial was established by WHO to find an effective COVID-19 treatment for hospitalized patients.</p> <p dir="ltr">The International Steering Committee formulated the recommendation in light of the evidence for hydroxychloroquine vs standard-of-care and for lopinavir/ritonavir vs standard-of-care from the Solidarity trial interim results, and from a review of the evidence from all trials presented at the 1-2 July WHO Summit on COVID-19 research and innovation. </p> <p dir="ltr">These interim trial results show that hydroxychloroquine and lopinavir/ritonavir produce little or no reduction in the mortality of hospitalized COVID-19 patients when compared to standard of care. Solidarity trial investigators will interrupt the trials with immediate effect. </p> <p dir="ltr">For each of the drugs, the interim results do not provide solid evidence of increased mortality. There were, however, some associated safety signals in the clinical laboratory findings of the add-on Discovery trial, a participant in the Solidarity trial. These will also be reported in the peer-reviewed publication. </p> <p dir="ltr">This decision applies only to the conduct of the Solidarity trial in hospitalized patients and does not affect the possible evaluation in other studies of hydroxychloroquine or lopinavir/ritonavir in non-hospitalized patients or as pre- or post-exposure prophylaxis for COVID-19. The interim Solidarity results are now being readied for peer-reviewed publication.</p> <div><br></div> <div><br></div>
- Timeline of WHO’s response to COVID-19WHO provides this timeline of the organization’s COVID-19 response activities for general information. WHO will update the timeline on a regular basis and in light of evolving events and new information. Unless noted otherwise, country-specific information and data are as reported to WHO by its Member States. This timeline continues in the spirit of, and supersedes, the WHO Rolling Updates and the WHO Timeline statement published in April 2020. It is not intended to be exhaustive and does not contain details of every event or WHO activity. As of 29 June 2020, the following milestones and events focused on COVID-19 have taken place: • The Director-General and Executive Director of the WHO Health Emergencies Programme have held 74 media briefings. The Director-General's opening remarks, transcripts, videos and audio recordings for these media briefings are available online. • There have been 23 Member State Briefings and information sessions. • EPI-WIN, WHO’s information network for epidemics, has convened 60 technical webinars, making available 287 expert panellists to more than 13,500 participants, from more than 120 countries and territories, with representation from as many as 460 organizations. • The OpenWHO platform has had more than 2.7 million enrolments in its COVID-19 courses. Free training is available on 13 different topics translated into 31 languages to support the coronavirus response, for a total of 100 COVID-19 courses. • WHO’s landscape of COVID-19 candidate vaccines lists 17 candidate vaccines in clinical evaluation and 132 in preclinical evaluation. In addition to the selected guidance included below, all of WHO’s technical guidance on COVID-19 can be found online here. All events listed below are in the Geneva, Switzerland time zone (CET/CEST). Note that the dates listed for documents are based on when they were finalised and timestamped.
- Real Health Podcast: The Lessons Learned from the Operation Transformation LeadersWith this year’s Operation Transformation reaching its finale I wanted to catch up with the five leaders to find out more about their incredible journey.
- Explainer: Leo Varadkar is 40 but has a metabolic age of 53 - why is that and how can he improve it?Metabolic testing is widely available at gyms, universities and medical clinics - but just how accurate is it and will the data help you lose weight?
- Experts hail 'hugely exciting' advance in treatment for deadly breast cancerThousands of women with the most deadly form of breast cancer could be given hope by a breakthrough treatment which could make chemotherapy effective.
What can I expect?
Most commonly reported symptoms
Most commonly reported symptoms
The most commonly reported symptoms of the coronavirus are as listed below:
- A cough (any kind of cough, not just dry)
- Shortness of breath
- Breathing difficulties
COVID-19 Public Health Advice
Experiencing any symptoms?
Experiencing any symptoms?
If you are experiencing any of the symptoms, do not panic.
- Engage in a MedBot consult to ascertain your personal risk assessment
- Follow the resulting guidelines for your next steps based on HSE and WHO recommendations. (Source: HSE)
How the COVID Medbot works
Engage in a MedBot consult.
Ascertain your risk assessment based on the results of the MedBot.
Follow the resulting guidelines given by the MedBot based on HSE recommendations.
Much of the panic surrounding the novel coronavirus outbreak has come from several myths that have been circulating regarding the nature of the virus. We’re here to debunk those myths, and provide you with up to date information from the HSE and WHO.
“Wearing a mask will protect me from the virus”
Standard surgical masks cannot protect you from the new coronavirus, as they are not designed to block out viral particles and often do not lay flush to the face. Using masks is unlikely to be of any benefit if you are not sick. However, there may be a benefit for sick people to use a mask to prevent the spread of infected droplets to other people.
“Cold weather and snow can kill the coronavirus”
There is no reason to believe that cold weather can kill the new coronavirus or other diseases, as the normal human body temperature remains around 37ºC regardless of external temperature or weather.
“Hand dryers can kill the new coronavirus”
No, hand dryers are not effective in killing COVID-19. To protect yourself against the new coronavirus you should frequently clean your hands with an alcohol-based hand rub, or wash them with soap and water. Once your hands are cleaned, you should dry them thoroughly by using paper towels or a warm air dryer.
The AKKURE team possess a fusion of expertise in the medical, information engineering and healthcare space, with their current focus on the treatment of respiratory illnesses, rare diseases and oncology. Most notably, their founder Dr. Oran Rigby, a professor of robotics and autonomous systems, is also a consultant in intensive care medicine and surgery, whilst holding master’s degrees in disaster medicine, trauma surgery and orthopaedic medicine. Co-founder Dr Amy Hollingworth is a respiratory and lung transplant specialist, with a master’s degree in public health, focusing on pandemic influenza.
Singularity Alpha Limited (trading as Akkure4Covid.com), NovaUCD Innovation Centre, University College Dublin, Dublin 4, Ireland.
Please fill in the form below if you have any questions.